Eiji Kurosaki

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · European Journal of Pharmacology · 2013 · 305 citations

Obesity, Metabolic Syndrome, Inflammation +10

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Masanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki et al. · European Journal of Pharmacology · 2014 · 190 citations · Full text

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects

Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono et al. · Journal of Pharmacological Sciences · 2016 · 144 citations · Full text

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

Masakazu Imamura, Keita Nakanishi, Takayuki Suzuki et al. · Bioorganic & Medicinal Chemistry · 2012 · 130 citations · Full text

Medicinal Chemistry, Biochemistry, Benzothiophene Structure +10

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · Journal of Pharmacy and Pharmacology · 2014 · 122 citations